Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
Two Lab Cases Lead U.S. Patent Office to Update Interim Guidance on Natural Phenomena
...
Register
Senior Medicare Patrol Had Significant Drop in Fraud Recoveries Last Year
...
Register
AMP Offers Proposal for Regulation of Laboratory-Developed Tests
...
Register
CDC Investing $110 Million in Disease Surveillance and Detection
...
Register
Illumina-Backed Helix to Expand Consumer Genetics
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies Helix (San Francisco) believes it can vastly expand the nascent consumer genomics market. The company, which announced backing from sequencing giant Illumina (San Diego), will launch a pay-as-you...
Participants in Bundled Payment Pilot Take on Risk
By Kelly A. Briganti, Editorial Director, G2 Intelligence In a pilot project, more than 2,100 providers are increasing their skin in the game of value-based health care reimbursement by taking on financial risk. The Centers for Medicare & Medicaid Services (CMS)...
Roche Boosts Molecular Portfolio with Deals to Acquire GeneWEAVE, Kapa Biosystems
By Stephanie Murg, Managing Director, G2 Intelligence With some 60% of its therapeutic candidates now being co-developed with companion diagnostics, Roche (Basel, Switzerland) is investing in both its diagnostics business and its drug pipeline with two recently...
OPKO, Bio-Reference Complete Deal
By Ron Shinkman, Editor, Laboratory Industry Report Miami-based OPKO Health has completed its acquisition of New Jersey-based Bio-Reference Laboratories. Under the terms of the all-stock deal, Bio-Reference shareholders received 2.75 shares of OPKO stock in a deal...
Rise in Lyme Cases Drives Interest in New Tests
...
Register
HCV Testing Strategies Falling Short in Reach
...
Register